Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | EGFR | P00533 | 1/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.43 |
| ▸ | TNKS | O95271 | 1/20 | 0.43 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.43 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.43 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.43 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.43 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28944425 | 1.00 | CYP2C19 (0.57) | CYP2C19MAOBEGFRGLATDP1 | |
| SCHEMBL560994 | 1.00 | CYP2C19 (0.57) | CYP2C19MAOBEGFRGLATDP1 | |
| SCHEMBL7903413 | 0.86 | CYP2C19 (0.57) | CYP2C19MAOBEGFRGLATDP1 | |
| SCHEMBL9907145 | 0.82 | CYP2C19 (0.53) | CYP2C19MAOBEGFRGLATDP1 | |
| SCHEMBL15689522 | 0.80 | CYP2C19 (0.52) | CYP2C19MAOBEGFRGLATDP1 | |
| SCHEMBL9906171 | 0.80 | CYP2C19 (0.52) | CYP2C19MAOBEGFRGLATDP1 | |
| SCHEMBL28939716 | 0.80 | CYP2C19 (0.55) | CYP2C19MAOBEGFRGLATDP1 | |
| SCHEMBL26917 | 0.80 | CYP2C19 (0.55) | CYP2C19MAOBEGFRGLATDP1 | |
| SCHEMBL3340845 | 0.80 | MAOB (0.50) | CYP2C19MAOBGLATDP1ALDH1A1 | |
| SCHEMBL18903348 | 0.80 | MAOB (0.50) | CYP2C19MAOBGLATDP1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110526802-B | Monomer, polymer, negative resist composition, photomask blank, and resist pattern forming method | 信越化学工业株式会社 | 2022-09-20 | — | — | CN | disclosed |
| CN-111263838-A | Fragrance composition for inhibiting off-flavor | 株式会社LG生活健康 | 2020-06-09 | — | — | CN | disclosed |
| CN-110526802-A | Monomer, polymer, negative resist composition, photo blanks and resist pattern forming method | SHINETSU CHEMICAL CO | 2019-12-03 | — | — | CN | disclosed |
| US-8420698-B2 | Histone deacetylase inhibitors | ERRANT GENE THERAPEUTICS, LLC (US) | 2013-04-16 | — | — | US | disclosed |
| US-20120035257-A1 | Histone Deacetylase Inhibitors | ERRANT GENE THERAPEUTICS, LLC | 2012-02-09 | — | — | US | disclosed |
| US-20110287535-A1 | Histone Deacetylase Inhibitors | ERRANT GENE THERAPEUTICS, LLC | 2011-11-24 | — | — | US | disclosed |
| US-20110288168-A1 | HISTONE DEACETYLASE INHIBITORS | ERRANT GENE THERAPEUTICS, LLC | 2011-11-24 | — | — | US | disclosed |
| US-8026280-B2 | For therapy of cancer, hematological disorders, e.g., hemoglobinopathies, and genetic related metabolic disorders, e.g., cystic fibrosis and adrenoleukodystrophy. | ERRANT GENE THERAPEUTICS, LLC (US) | 2011-09-27 | — | — | US | disclosed |
| US-7902259-B2 | with zinc-binding activities; 5-phenyl-2,4,-pentadienoyl hydroxamic acid; gene expression inhibitor; anticarcinogenic, antitumor, antiprotozoa agent, viricide; hematological disorders, hemoglobinopathies, genetic related metabolic disorders, cystic fibrosis | ERRANT GENE THERAPEUTICS, LLC (US) | 2011-03-08 | — | — | US | disclosed |
| US-7858664-B2 | Histone deacetylase inhibitors | ERRANT GENE THERAPEUTICS, LLC (US) | 2010-12-28 | — | — | US | disclosed |
| EP-1408946-A2 | HISTONE DEACETYLASE INHIBITORS | Circagen Pharmaceutical (US) | 2004-04-21 | — | — | EP | disclosed |
| US-20030125306-A1 | Histone deacetylase inhibitors | CIRCAGEN PHARMACEUTICAL, A DELAWARE CORPORATION | 2003-07-03 | — | — | US | disclosed |
| US-20030083521-A1 | Such as 5-phenyl-2,4-pentadienoylhydroxamic acid; for treating cancer, hematopoiesis, and genetic metabolic disorders (cystic fibrosis and adrenoleukodystrophy) | CIRCAGEN PHARMACEUTICAL, A MARYLAND CORPORATION | 2003-05-01 | — | — | US | disclosed |
| US-6495719-B2 | FOR USE IN THERAPY OF CANCER, HEMATOLOGICAL DISORDERS, SUCH AS HEMATOPOIESIS, AND GENETIC RELATED METABOLIC DISORDERS, SUCH AS, CYSTIC FIBROSIS AND ADRENOLEUKODYSTROPHY | CIRCAGEN PHARMACEUTICAL | 2002-12-17 | — | — | US | disclosed |
| WO-2002076941-A2 | HISTONE DEACETYLASE INHIBITORS | CIRCAGEN PHARMACEUTICAL (US) | 2002-10-03 | — | — | WO | disclosed |
| US-20020143037-A1 | Histone deacetylase inhibitors | CIRCAGEN PHARMACEUTICAL, A DELAWARE CORPORATION | 2002-10-03 | — | — | US | disclosed |
| US-20020143052-A1 | Histone deacetylase inhibitors | ANGELA CHEN SABELLA | 2002-10-03 | — | — | US | disclosed |
| US-20020143196-A1 | Histone deacetylase inhibitors | ERRANT GENE THERAPEUTICS, LLC | 2002-10-03 | — | — | US | disclosed |
| EP-0945420-A1 | Process for the preparation of bisphenols | Mitsui Chemicals, Inc. (JP) | 1999-09-29 | — | — | EP | disclosed |
| US-4070374-A | Process for the preparation of aryl substituted aldehydes, ketones and alcohols | GIVAUDAN CORPORATION (US) | 1978-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035257-A1 | Histone Deacetylase Inhibitors | HDAC1, HDAC11, HDAC9 | CYP2C19 2302/4885MAOB 1386/4885EGFR 4173/4885 |
| US-20030083521-A1 | Such as 5-phenyl-2,4-pentadienoylhydroxamic acid; for treating cancer, hematopoiesis, and genetic metabolic disorders (cystic fibrosis and adrenoleukodystrophy) | ZFX, HDAC5, ZNF277 | CYP2C19 3032/4885MAOB 3351/4885EGFR 4435/4885 |
| US-20020143052-A1 | Histone deacetylase inhibitors | HDAC1, HDAC11, HDAC9 | CYP2C19 2560/4885MAOB 1639/4885EGFR 4280/4885 |
| US-20030125306-A1 | Histone deacetylase inhibitors | HDAC1, HDAC11, HDAC9 | CYP2C19 2560/4885MAOB 1639/4885EGFR 4280/4885 |
| US-20020143196-A1 | Histone deacetylase inhibitors | HDAC1, HDAC11, HDAC5 | CYP2C19 4041/4885MAOB 2821/4885EGFR 4554/4885 |
| US-20020143037-A1 | Histone deacetylase inhibitors | HDAC1, HDAC9, HDAC11 | CYP2C19 2007/4885MAOB 1235/4885EGFR 4233/4885 |
| US-20110288168-A1 | HISTONE DEACETYLASE INHIBITORS | HDAC1, HDAC6, HDAC5 | CYP2C19 3448/4885MAOB 1159/4885EGFR 3976/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.